evelo
biosciences
treats
first
patients
phase
trial
treatment
psoriasis
interim
data
expected
cambridge
globe
newswire
evelo
biosciences
nasdaq
evlo
clinical
stage
biotechnology
company
developing
new
modality
orally
delivered
systemically
acting
biologics
today
announced
dosed
first
patients
phase
clinical
trial
evaluating
treatment
mild
moderate
psoriasis
investigational
oral
biologic
development
treatment
inflammatory
diseases
including
psoriasis
atopic
dermatitis
pleased
announce
dosing
first
patients
phase
clinical
trial
mild
moderate
psoriasis
said
duncan
mchale
chief
medical
officer
evelo
phase
studies
demonstrated
ability
resolve
systemic
inflammation
provide
clinical
benefit
patients
psoriasis
based
data
may
offer
improved
profile
existing
products
others
development
potential
effective
convenient
medicine
millions
patients
mild
moderate
psoriasis
phase
trial
successful
enable
us
advance
confirmatory
registrational
studies
following
meetings
health
authorities
food
drug
administration
fda
european
medicines
agency
ema
look
forward
interim
data
continue
progress
important
therapy
toward
phase
trial
designed
evaluate
three
doses
enteric
capsule
formulation
versus
placebo
patients
mild
moderate
psoriasis
treatment
period
primary
endpoint
mean
reduction
psoriasis
area
severity
index
pasi
score
weeks
key
secondary
endpoints
include
clinical
measures
disease
physician
global
assessment
pga
body
surface
area
bsa
pga
x
bsa
psoriasis
symptom
inventory
psi
dermatology
life
quality
index
dlqi
lesion
severity
score
lss
interim
data
study
expected
psoriasis
investigational
oral
biologic
developed
treatment
inflammatory
diseases
strain
prevotella
histicola
selected
specific
pharmacology
second
third
quarter
evelo
reported
positive
phase
interim
clinical
data
two
cohorts
patients
mild
moderate
psoriasis
well
tolerated
doses
overall
difference
reported
placebo
reduction
mean
lss
pasi
score
days
dosing
cohorts
received
high
dose
cohort
alone
continued
reduction
mean
lss
placebo
pasi
score
placebo
days
days
following
last
dose
drug
may
indicate
sustained
clinical
effect
dose
response
also
observed
limit
systemic
production
multiple
inflammatory
cytokines
including
tnf
mediators
potentially
harmful
effects
patients
inflammatory
diseases
psoriasis
psoriasis
common
chronic
inflammatory
skin
disease
affecting
population
worldwide
disease
driven
results
formation
thickened
red
plaques
scaling
psoriatic
lesions
appear
anywhere
body
often
seen
knees
elbows
scalp
lumbar
area
strong
association
psoriatic
arthritis
depression
metabolic
syndrome
patients
mild
moderate
psoriasis
underserved
current
treatments
including
topical
therapies
control
systemic
inflammation
low
rates
compliance
case
potent
topical
steroids
recommended
use
majority
novel
therapies
including
injectable
biologics
approved
patients
moderate
severe
disease
even
patient
population
majority
eligible
patients
receive
biologics
instead
opting
topical
oral
systemic
therapies
associated
tolerability
issues
monitoring
requirements
tied
safety
concerns
evelo
biosciences
evelo
biosciences
clinical
stage
biotechnology
company
developing
oral
biologics
act
small
intestinal
axis
systemic
therapeutic
effects
sintax
plays
central
role
governing
immune
metabolic
neurological
systems
company
first
product
candidates
pharmaceutical
preparations
single
strains
microbes
selected
defined
pharmacological
properties
evelo
therapies
potential
effective
safe
affordable
medicines
improve
lives
people
inflammatory
diseases
cancer
evelo
currently
four
product
candidates
development
treatment
inflammatory
diseases
including
psoriasis
atopic
dermatitis
treatment
cancer
evelo
advancing
additional
product
candidates
disease
areas
information
please
visit
engage
evelo
linkedin
forward
looking
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
statements
contained
press
release
relate
matters
historical
fact
considered
statements
including
statements
concerning
timing
results
clinical
trials
readouts
development
plans
promise
potential
impact
product
candidates
statements
based
management
current
expectations
statements
neither
promises
guarantees
involve
known
unknown
risks
uncertainties
important
factors
may
cause
actual
results
performance
achievements
materially
different
future
results
performance
achievements
expressed
implied
statements
including
limited
following
impact
pandemic
operations
including
preclinical
studies
clinical
trials
continuity
business
incurred
significant
losses
currently
profitable
may
never
become
profitable
need
additional
funding
limited
operating
history
unproven
approach
therapeutic
intervention
lengthy
expensive
uncertain
process
clinical
drug
development
including
potential
delays
regulatory
approval
reliance
third
parties
collaborators
expand
microbial
library
conduct
clinical
trials
manufacture
product
candidates
develop
commercialize
product
candidates
approved
lack
experience
manufacturing
selling
marketing
distributing
product
candidates
failure
compete
successfully
drug
companies
protection
proprietary
technology
confidentiality
trade
secrets
potential
lawsuits
claims
infringement
intellectual
property
challenges
ownership
intellectual
property
patents
found
invalid
unenforceable
risks
associated
international
operations
ability
retain
key
personnel
manage
growth
potential
volatility
common
stock
management
principal
stockholders
ability
control
significantly
influence
business
costs
resources
operating
public
company
unfavorable
analyst
research
reports
securities
class
action
litigation
us
important
factors
discussed
caption
risk
factors
quarterly
report
form
quarter
ended
june
reports
filed
sec
could
cause
actual
results
differ
materially
indicated
statements
made
press
release
statements
represent
management
estimates
date
press
release
may
elect
update
statements
point
future
except
required
law
disclaim
obligation
even
subsequent
events
cause
views
change
statements
relied
upon
representing
views
date
subsequent
date
press
release
